Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Diseases 1Colorectal Neoplasms 1Chromosome 17 deletion 1Breast Neoplasms 1

Interventions

Rituximab 155Cyclophosphamide 120fludarabine phosphate 71Whole-Body Irradiation 55Mycophenolic Acid 54Etoposide 53Peripheral Blood Stem Cell Transplantation 46fludarabine 45Melphalan 44Granulocyte Colony-Stimulating Factor 43Busulfan 43Tacrolimus 39Filgrastim 37Vincristine 33Cyclosporine 31Bendamustine Hydrochloride 31Prednisone 29Doxorubicin 29Antilymphocyte Serum 28Methotrexate 27Cytarabine 27Lenalidomide 23Carmustine 22Bortezomib 22plerixafor 20Dexamethasone 19Thiotepa 17Stem Cell Transplantation 17Radiotherapy 17tositumomab I-131 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Non-Hodgkin × RG7388 × Clear all
NCT02624986 2020-05-18

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Hoffmann-La Roche

Phase 1/2 Terminated
25 enrolled 21 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡